Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
To require the Treasury to take a more prominent role in coordinating AML/CFT policy and examinations across the Government, and for other purposes.
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytics dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect renumeration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services; H.R. 6688, The Analyzing and Leveraging Existing Rx Transactions (ALERT) Act.
To require the Treasury to take a more prominent role in coordinating AML/CFT policy and examinations across the Government, and for other purposes.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
USTR Section 301 proposed tariffs.
Implementation of Comprehensive Addiction and Recovery Act (CARA) PL 114-198 and education regarding opioid treatment and prevention; Implementation of 21st Century Cures (H.R. 34), advocacy related to healthcare technology and innovation issues; E-Rx (H.R.3528), advocacy related to electronic prescriptions of medications; Implementation of FY'2018 NDAA provision related to e-Commerce portals; education about potential improvements to Prescription Drug Monitoring Programs; H.R. 6 Substance Use- Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act; Education about improvements to Prescription Drug Monitoring programs that would promote greater efficiency and utility at the pharmacy and other issues related to opioid abuse.
Source: Senate LDA
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytics dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect renumeration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services; H.R. 6688, The Analyzing and Leveraging Existing Rx Transactions (ALERT) Act.
To require the Treasury to take a more prominent role in coordinating AML/CFT policy and examinations across the Government, and for other purposes.
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytics dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect renumeration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services; H.R. 6688, The Analyzing and Leveraging Existing Rx Transactions (ALERT) Act.
Federal Labor-Management Partnership Act of 2019
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytics dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect renumeration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services; H.R. 6688, The Analyzing and Leveraging Existing Rx Transactions (ALERT) Act.
Federal Labor-Management Partnership Act of 2019
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytics dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect renumeration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services; H.R. 6688, The Analyzing and Leveraging Existing Rx Transactions (ALERT) Act.
Federal Labor-Management Partnership Act of 2019
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytics dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect renumeration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services; H.R. 6688, The Analyzing and Leveraging Existing Rx Transactions (ALERT) Act.
The Opportunity Project Act of 2019
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Implementation of Comprehensive Addiction and Recovery Act (CARA) PL 114-198 and education regarding opioid treatment and prevention; Implementation of 21st Century Cures (H.R. 34), advocacy related to healthcare technology and innovation issues; E-Rx (H.R.3528), advocacy related to electronic prescriptions of medications; Implementation of FY'2018 NDAA provision related to e-Commerce portals; education about potential improvements to Prescription Drug Monitoring Programs; H.R. 6 Substance Use- Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act; Education about improvements to Prescription Drug Monitoring programs that would promote greater efficiency and utility at the pharmacy and other issues related to opioid abuse.
The Opportunity Project Act of 2019
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Implementation of Comprehensive Addiction and Recovery Act (CARA) PL 114-198 and education regarding opioid treatment and prevention; Implementation of 21st Century Cures (H.R. 34), advocacy related to healthcare technology and innovation issues; E-Rx (H.R.3528), advocacy related to electronic prescriptions of medications; Implementation of FY'2018 NDAA provision related to e-Commerce portals; education about potential improvements to Prescription Drug Monitoring Programs; H.R. 6 Substance Use- Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act; Education about improvements to Prescription Drug Monitoring programs that would promote greater efficiency and utility at the pharmacy and other issues related to opioid abuse.
The Opportunity Project Act of 2019
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Implementation of Comprehensive Addiction and Recovery Act (CARA) PL 114-198 and education regarding opioid treatment and prevention; Implementation of 21st Century Cures (H.R. 34), advocacy related to healthcare technology and innovation issues; E-Rx (H.R.3528), advocacy related to electronic prescriptions of medications; Implementation of FY'2018 NDAA provision related to e-Commerce portals; education about potential improvements to Prescription Drug Monitoring Programs; H.R. 6 Substance Use- Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act; Education about improvements to Prescription Drug Monitoring programs that would promote greater efficiency and utility at the pharmacy and other issues related to opioid abuse.
To repeal the debt ceiling.
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Physician and pharmacy reimbursement issues;Legislation to amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare; Site neutral payment reforms;Issues related to physician reimbursement for Part B drugs;Support for increased transparency and accountability in Medicare's local determination process (S.794/H.R. 3635); Issues as they relate to opioid abuse policy; General Medicare/Medicaid Issues; Issues related to reimbursement for radiation therapy services; 340B, education related to need for sensible reforms in 340B that protect indigent beneficiaries and community oncology practices; Pandemic and All Hazards Preparedness Act reauthorization; issues related to step therapy policies in Medicare Advantage plans; Medicare physician payment; Issues related to an alternative payment model for radiation oncology services; Issues related to the Center for Medicare and Medicaid Innovation; Issues related to the ANPRM International Pricing Index Model for Medicare Part B Drugs; Chimeric Antigen Receptor (CAR) T-Cell Therapy coverage.
To repeal the debt ceiling.
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Physician and pharmacy reimbursement issues;Legislation to amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare; Site neutral payment reforms;Issues related to physician reimbursement for Part B drugs;Support for increased transparency and accountability in Medicare's local determination process (S.794/H.R. 3635); Issues as they relate to opioid abuse policy; General Medicare/Medicaid Issues; Issues related to reimbursement for radiation therapy services; 340B, education related to need for sensible reforms in 340B that protect indigent beneficiaries and community oncology practices; Pandemic and All Hazards Preparedness Act reauthorization; issues related to step therapy policies in Medicare Advantage plans; Medicare physician payment; Issues related to an alternative payment model for radiation oncology services; Issues related to the Center for Medicare and Medicaid Innovation; Issues related to the ANPRM International Pricing Index Model for Medicare Part B Drugs; Chimeric Antigen Receptor (CAR) T-Cell Therapy coverage.
To repeal the debt ceiling.
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Physician and pharmacy reimbursement issues;Legislation to amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare; Site neutral payment reforms;Issues related to physician reimbursement for Part B drugs;Support for increased transparency and accountability in Medicare's local determination process (S.794/H.R. 3635); Issues as they relate to opioid abuse policy; General Medicare/Medicaid Issues; Issues related to reimbursement for radiation therapy services; 340B, education related to need for sensible reforms in 340B that protect indigent beneficiaries and community oncology practices; Pandemic and All Hazards Preparedness Act reauthorization; issues related to step therapy policies in Medicare Advantage plans; Medicare physician payment; Issues related to an alternative payment model for radiation oncology services; Issues related to the Center for Medicare and Medicaid Innovation; Issues related to the ANPRM International Pricing Index Model for Medicare Part B Drugs; Chimeric Antigen Receptor (CAR) T-Cell Therapy coverage.
Protect Veterans from Financial Fraud Act of 2019
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytics dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect renumeration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services; H.R. 6688, The Analyzing and Leveraging Existing Rx Transactions (ALERT) Act.
Protect Veterans from Financial Fraud Act of 2019
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytics dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect renumeration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services; H.R. 6688, The Analyzing and Leveraging Existing Rx Transactions (ALERT) Act.
Protect Veterans from Financial Fraud Act of 2019
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytics dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect renumeration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services; H.R. 6688, The Analyzing and Leveraging Existing Rx Transactions (ALERT) Act.
SNAP COVID–19 Anti-Hunger Restaurant Relief for You Act of 2020
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytics dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect renumeration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services; H.R. 6688, The Analyzing and Leveraging Existing Rx Transactions (ALERT) Act.
SNAP COVID–19 Anti-Hunger Restaurant Relief for You Act of 2020
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytics dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect renumeration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services; H.R. 6688, The Analyzing and Leveraging Existing Rx Transactions (ALERT) Act.
SNAP COVID–19 Anti-Hunger Restaurant Relief for You Act of 2020
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytics dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect renumeration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services; H.R. 6688, The Analyzing and Leveraging Existing Rx Transactions (ALERT) Act.
Strengthening America's Security in the Middle East Act of 2019
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R./S.1: Tax Cuts and Jobs Act.
Strengthening America's Security in the Middle East Act of 2019
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R./S.1: Tax Cuts and Jobs Act.
Strengthening America's Security in the Middle East Act of 2019
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R./S.1: Tax Cuts and Jobs Act.
A bill for the relief of Jose Alberto Martinez Moreno, Micaela Lopez Martinez, and Adilene Martinez.
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Physician and pharmacy reimbursement issues;Legislation to amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare; Site neutral payment reforms;Issues related to physician reimbursement for Part B drugs;Support for increased transparency and accountability in Medicare's local determination process (S.794/H.R. 3635); Issues as they relate to opioid abuse policy; General Medicare/Medicaid Issues; Issues related to reimbursement for radiation therapy services; 340B, education related to need for sensible reforms in 340B that protect indigent beneficiaries and community oncology practices; Pandemic and All Hazards Preparedness Act reauthorization; issues related to step therapy policies in Medicare Advantage plans; Medicare physician payment; Issues related to an alternative payment model for radiation oncology services; Issues related to the Center for Medicare and Medicaid Innovation; Issues related to the ANPRM International Pricing Index Model for Medicare Part B Drugs; Chimeric Antigen Receptor (CAR) T-Cell Therapy coverage.
A bill for the relief of Jose Alberto Martinez Moreno, Micaela Lopez Martinez, and Adilene Martinez.
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Physician and pharmacy reimbursement issues;Legislation to amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare; Site neutral payment reforms;Issues related to physician reimbursement for Part B drugs;Support for increased transparency and accountability in Medicare's local determination process (S.794/H.R. 3635); Issues as they relate to opioid abuse policy; General Medicare/Medicaid Issues; Issues related to reimbursement for radiation therapy services; 340B, education related to need for sensible reforms in 340B that protect indigent beneficiaries and community oncology practices; Pandemic and All Hazards Preparedness Act reauthorization; issues related to step therapy policies in Medicare Advantage plans; Medicare physician payment; Issues related to an alternative payment model for radiation oncology services; Issues related to the Center for Medicare and Medicaid Innovation; Issues related to the ANPRM International Pricing Index Model for Medicare Part B Drugs; Chimeric Antigen Receptor (CAR) T-Cell Therapy coverage.
A bill for the relief of Jose Alberto Martinez Moreno, Micaela Lopez Martinez, and Adilene Martinez.
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Physician and pharmacy reimbursement issues;Legislation to amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare; Site neutral payment reforms;Issues related to physician reimbursement for Part B drugs;Support for increased transparency and accountability in Medicare's local determination process (S.794/H.R. 3635); Issues as they relate to opioid abuse policy; General Medicare/Medicaid Issues; Issues related to reimbursement for radiation therapy services; 340B, education related to need for sensible reforms in 340B that protect indigent beneficiaries and community oncology practices; Pandemic and All Hazards Preparedness Act reauthorization; issues related to step therapy policies in Medicare Advantage plans; Medicare physician payment; Issues related to an alternative payment model for radiation oncology services; Issues related to the Center for Medicare and Medicaid Innovation; Issues related to the ANPRM International Pricing Index Model for Medicare Part B Drugs; Chimeric Antigen Receptor (CAR) T-Cell Therapy coverage.
SUPPORT for Patients and Communities Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Implementation of Comprehensive Addiction and Recovery Act (CARA) PL 114-198 and education regarding opioid treatment and prevention; Implementation of 21st Century Cures (H.R. 34), advocacy related to healthcare technology and innovation issues; E-Rx (H.R.3528), advocacy related to electronic prescriptions of medications; Implementation of FY'2018 NDAA provision related to e-Commerce portals; education about potential improvements to Prescription Drug Monitoring Programs; H.R. 6 Substance Use- Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act; Education about improvements to Prescription Drug Monitoring programs that would promote greater efficiency and utility at the pharmacy and other issues related to opioid abuse.
SUPPORT for Patients and Communities Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Implementation of Comprehensive Addiction and Recovery Act (CARA) PL 114-198 and education regarding opioid treatment and prevention; Implementation of 21st Century Cures (H.R. 34), advocacy related to healthcare technology and innovation issues; E-Rx (H.R.3528), advocacy related to electronic prescriptions of medications; Implementation of FY'2018 NDAA provision related to e-Commerce portals; education about potential improvements to Prescription Drug Monitoring Programs; H.R. 6 Substance Use- Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act; Education about improvements to Prescription Drug Monitoring programs that would promote greater efficiency and utility at the pharmacy and other issues related to opioid abuse.
SUPPORT for Patients and Communities Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Implementation of Comprehensive Addiction and Recovery Act (CARA) PL 114-198 and education regarding opioid treatment and prevention; Implementation of 21st Century Cures (H.R. 34), advocacy related to healthcare technology and innovation issues; E-Rx (H.R.3528), advocacy related to electronic prescriptions of medications; Implementation of FY'2018 NDAA provision related to e-Commerce portals; education about potential improvements to Prescription Drug Monitoring Programs; H.R. 6 Substance Use- Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act; Education about improvements to Prescription Drug Monitoring programs that would promote greater efficiency and utility at the pharmacy and other issues related to opioid abuse.
21st Century Cures Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Implementation of Comprehensive Addiction and Recovery Act (CARA) PL 114-198 and education regarding opioid treatment and prevention; Implementation of 21st Century Cures (H.R. 34), advocacy related to healthcare technology and innovation issues; E-Rx (H.R.3528), advocacy related to electronic prescriptions of medications; Implementation of FY'2018 NDAA provision related to e-Commerce portals; education about potential improvements to Prescription Drug Monitoring Programs; H.R. 6 Substance Use- Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act; Education about improvements to Prescription Drug Monitoring programs that would promote greater efficiency and utility at the pharmacy and other issues related to opioid abuse.
21st Century Cures Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Implementation of Comprehensive Addiction and Recovery Act (CARA) PL 114-198 and education regarding opioid treatment and prevention; Implementation of 21st Century Cures (H.R. 34), advocacy related to healthcare technology and innovation issues; E-Rx (H.R.3528), advocacy related to electronic prescriptions of medications; Implementation of FY'2018 NDAA provision related to e-Commerce portals; education about potential improvements to Prescription Drug Monitoring Programs; H.R. 6 Substance Use- Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act; Education about improvements to Prescription Drug Monitoring programs that would promote greater efficiency and utility at the pharmacy and other issues related to opioid abuse.
21st Century Cures Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Implementation of Comprehensive Addiction and Recovery Act (CARA) PL 114-198 and education regarding opioid treatment and prevention; Implementation of 21st Century Cures (H.R. 34), advocacy related to healthcare technology and innovation issues; E-Rx (H.R.3528), advocacy related to electronic prescriptions of medications; Implementation of FY'2018 NDAA provision related to e-Commerce portals; education about potential improvements to Prescription Drug Monitoring Programs; H.R. 6 Substance Use- Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act; Education about improvements to Prescription Drug Monitoring programs that would promote greater efficiency and utility at the pharmacy and other issues related to opioid abuse.
Improving Transparency and Accuracy in Medicare Part D Spending Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytics dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect renumeration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services.
Improving Transparency and Accuracy in Medicare Part D Spending Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytics dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect renumeration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services; H.R. 6688, The Analyzing and Leveraging Existing Rx Transactions (ALERT) Act.
Improving Transparency and Accuracy in Medicare Part D Spending Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytics dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect renumeration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services; Issues related to reimbursement from the Department of Veterans Affairs.
Improving Transparency and Accuracy in Medicare Part D Spending Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytics dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect renumeration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services; H.R. 6688, The Analyzing and Leveraging Existing Rx Transactions (ALERT) Act.
Improving Transparency and Accuracy in Medicare Part D Spending Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytics dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect renumeration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services.
Prescription Drug Price Transparency Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytics dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect renumeration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services.
Prescription Drug Price Transparency Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytics dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect renumeration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services; H.R. 6688, The Analyzing and Leveraging Existing Rx Transactions (ALERT) Act.
Prescription Drug Price Transparency Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytics dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect renumeration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services; Issues related to reimbursement from the Department of Veterans Affairs.
Prescription Drug Price Transparency Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytics dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect renumeration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services.
Prescription Drug Price Transparency Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytics dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect renumeration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services; H.R. 6688, The Analyzing and Leveraging Existing Rx Transactions (ALERT) Act.
Every Prescription Conveyed Securely Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Implementation of Comprehensive Addiction and Recovery Act (CARA) PL 114-198 and education regarding opioid treatment and prevention; Implementation of 21st Century Cures (H.R. 34), advocacy related to healthcare technology and innovation issues; E-Rx (H.R.3528), advocacy related to electronic prescriptions of medications; Implementation of FY'2018 NDAA provision related to e-Commerce portals; education about potential improvements to Prescription Drug Monitoring Programs; H.R. 6 Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act.
Every Prescription Conveyed Securely Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Implementation of Comprehensive Addiction and Recovery Act (CARA) PL 114-198 and education regarding opioid treatment and prevention; Implementation of 21st Century Cures (H.R. 34), advocacy related to healthcare technology and innovation issues; E-Rx (H.R.3528), advocacy related to electronic prescriptions of medications; Implementation of FY'2018 NDAA provision related to e-Commerce portals; education about potential improvements to Prescription Drug Monitoring Programs; H.R. 6 Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act; Education about improvements to Prescription Drug Monitoring programs that would promote greater efficiency and utility at the pharmacy and other issues related to opioid abuse.
Every Prescription Conveyed Securely Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Implementation of Comprehensive Addiction and Recovery Act (CARA) PL 114-198 and education regarding opioid treatment and prevention; Implementation of 21st Century Cures (H.R. 34), advocacy related to healthcare technology and innovation issues; E-Rx (H.R.3528), advocacy related to electronic prescriptions of medications.
Every Prescription Conveyed Securely Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Implementation of Comprehensive Addiction and Recovery Act (CARA) PL 114-198 and education regarding opioid treatment and prevention; Implementation of 21st Century Cures (H.R. 34), advocacy related to healthcare technology and innovation issues; E-Rx (H.R.3528), advocacy related to electronic prescriptions of medications; Implementation of FY'2018 NDAA provision related to e-Commerce portals;education about potential improvements to Prescription Drug Monitoring Programs.
Every Prescription Conveyed Securely Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Implementation of Comprehensive Addiction and Recovery Act (CARA) PL 114-198 and education regarding opioid treatment and prevention; Implementation of 21st Century Cures (H.R. 34), advocacy related to healthcare technology and innovation issues; E-Rx (H.R.3528), advocacy related to electronic prescriptions of medications; Implementation of FY'2018 NDAA provision related to e-Commerce portals; education about potential improvements to Prescription Drug Monitoring Programs; H.R. 6 Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act.
Local Coverage Determination Clarification Act of 2018
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Physician and pharmacy reimbursement issues; Legislation to amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare; Site neutral payment reforms; Issues related to physician reimbursement for Part B drugs; Support for increased transparency and accountability in Medicare's local determination process (S.794/H.R. 3635); Issues as they relate to opioid abuse policy; General Medicare/Medicaid Issues; Issues related to reimbursement for radiation therapy services; 340B, education related to need for sensible reforms in 340B that protect indigent beneficiaries and community oncology practices; Pandemic and All Hazards Preparedness Act reauthorization.
Local Coverage Determination Clarification Act of 2018
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Physician and pharmacy reimbursement issues; Legislation to amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare; Site neutral payment reforms;Issues related to physician reimbursement for Part B drugs;Support for increased transparency and accountability in Medicare's local determination process (S.794/H.R. 3635); Issues as they relate to opioid abuse policy; General Medicare/Medicaid Issues; Issues related to reimbursement for radiation therapy services; 340B, education related to need for sensible reforms in 340B that protect indigent beneficiaries and community oncology practices; Pandemic and All Hazards Preparedness Act reauthorization; issues related to step therapy policies in Medicare Advantage plans; Medicare physician payment; Issues related to an alternative payment model for radiation oncology services; Issues related to the Center for Medicare and Medicaid Innovation; Issues related to the ANPRM International Pricing Index Model for Medicare Part B Drugs.
Local Coverage Determination Clarification Act of 2018
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Physician and pharmacy reimbursement issues; Legislation to amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare; Site neutral payment reforms; Issues related to physician reimbursement for Part B drugs; Support for increased transparency and accountability in Medicare's local determination process (S.794/H.R. 3635); Issues as they relate to opioid abuse policy; General Medicare/Medicaid Issues; Issues related to reimbursement for radiation therapy services; 340B, education related to need for sensible reforms in 340B that protect indigent beneficiaries and community oncology practices; Pandemic and All Hazards Preparedness Act reauthorization.
Local Coverage Determination Clarification Act of 2018
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Physician and pharmacy reimbursement issues; Legislation to amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare; Site neutral payment reforms; Issues related to physician reimbursement for Part B drugs; Support for increased transparency and accountability in Medicare's local determination process (S.794/H.R. 3635); Issues as they relate to opioid abuse policy; General Medicare/Medicaid Issues; Issues related to reimbursement for radiation therapy services; 340B, education related to need for sensible reforms in 340B that protect indigent beneficiaries and community oncology practices; Pandemic and All Hazards Preparedness Act reauthorization.
Local Coverage Determination Clarification Act of 2018
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Physician and pharmacy reimbursement issues; Legislation to amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare; Site neutral payment reforms; Issues related to physician reimbursement for Part B drugs; Support for increased transparency and accountability in Medicare's local determination process (S.794/H.R. 3635); Issues as they relate to opioid abuse policy; General Medicare/Medicaid Issues; Issues related to reimbursement for radiation therapy services; 340B, education related to need for sensible reforms in 340B that protect indigent beneficiaries and community oncology practices; Pandemic and All Hazards Preparedness Act reauthorization; issues related to step therapy policies in Medicare Advantage plans; Medicare physician payment.
Pharmacy and Medically Underserved Areas Enhancement Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytics dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect renumeration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services; Issues related to reimbursement from the Department of Veterans Affairs.
Pharmacy and Medically Underserved Areas Enhancement Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytics dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect renumeration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services.
Pharmacy and Medically Underserved Areas Enhancement Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytics dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect renumeration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services; H.R. 6688, The Analyzing and Leveraging Existing Rx Transactions (ALERT) Act.
Pharmacy and Medically Underserved Areas Enhancement Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytics dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect renumeration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services.
Pharmacy and Medically Underserved Areas Enhancement Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytics dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect renumeration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services; H.R. 6688, The Analyzing and Leveraging Existing Rx Transactions (ALERT) Act.
SUPPORT for Patients and Communities Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Implementation of Comprehensive Addiction and Recovery Act (CARA) PL 114-198 and education regarding opioid treatment and prevention; Implementation of 21st Century Cures (H.R. 34), advocacy related to healthcare technology and innovation issues; E-Rx (H.R.3528), advocacy related to electronic prescriptions of medications; Implementation of FY'2018 NDAA provision related to e-Commerce portals; education about potential improvements to Prescription Drug Monitoring Programs; H.R. 6 Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act.
SUPPORT for Patients and Communities Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Implementation of Comprehensive Addiction and Recovery Act (CARA) PL 114-198 and education regarding opioid treatment and prevention; Implementation of 21st Century Cures (H.R. 34), advocacy related to healthcare technology and innovation issues; E-Rx (H.R.3528), advocacy related to electronic prescriptions of medications; Implementation of FY'2018 NDAA provision related to e-Commerce portals; education about potential improvements to Prescription Drug Monitoring Programs; H.R. 6 Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act.
SUPPORT for Patients and Communities Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Implementation of Comprehensive Addiction and Recovery Act (CARA) PL 114-198 and education regarding opioid treatment and prevention; Implementation of 21st Century Cures (H.R. 34), advocacy related to healthcare technology and innovation issues; E-Rx (H.R.3528), advocacy related to electronic prescriptions of medications; Implementation of FY'2018 NDAA provision related to e-Commerce portals; education about potential improvements to Prescription Drug Monitoring Programs; H.R. 6 Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act; Education about improvements to Prescription Drug Monitoring programs that would promote greater efficiency and utility at the pharmacy and other issues related to opioid abuse.
ALERT Act of 2018
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytics dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect renumeration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services; H.R. 6688, The Analyzing and Leveraging Existing Rx Transactions (ALERT) Act.
ALERT Act of 2018
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytics dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect renumeration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services; H.R. 6688, The Analyzing and Leveraging Existing Rx Transactions (ALERT) Act.
An original bill to provide for reconciliation pursuant to title II of the concurrent resolution on the budget for fiscal year 2018.
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R./S.1: Tax Cuts and Jobs Act.
An original bill to provide for reconciliation pursuant to title II of the concurrent resolution on the budget for fiscal year 2018.
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R./S.1: Tax Cuts and Jobs Act.
An original bill to provide for reconciliation pursuant to title II of the concurrent resolution on the budget for fiscal year 2018.
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R./S.1: Tax Cuts and Jobs Act.
An original bill to provide for reconciliation pursuant to title II of the concurrent resolution on the budget for fiscal year 2018.
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R./S.1: Tax Cuts and Jobs Act.
An original bill to provide for reconciliation pursuant to title II of the concurrent resolution on the budget for fiscal year 2018.
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R./S.1: Tax Cuts and Jobs Act.
Local Coverage Determination Clarification Act of 2017
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Physician and pharmacy reimbursement issues; Legislation to amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare; Site neutral payment reforms; Issues related to physician reimbursement for Part B drugs; Support for increased transparency and accountability in Medicare's local determination process (S.794/H.R. 3635); Issues as they relate to opioid abuse policy; General Medicare/Medicaid Issues; Issues related to reimbursement for radiation therapy services; 340B, education related to need for sensible reforms in 340B that protect indigent beneficiaries and community oncology practices; Pandemic and All Hazards Preparedness Act reauthorization.
Local Coverage Determination Clarification Act of 2017
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Physician and pharmacy reimbursement issues; Legislation to amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare; Site neutral payment reforms; Issues related to physician reimbursement for Part B drugs; Support for increased transparency and accountability in Medicare's local determination process (S.794/H.R. 3635); Issues as they relate to opioid abuse policy; General Medicare/Medicaid Issues; Issues related to reimbursement for radiation therapy services; 340B, education related to need for sensible reforms in 340B that protect indigent beneficiaries and community oncology practices; Pandemic and All Hazards Preparedness Act reauthorization; issues related to step therapy policies in Medicare Advantage plans; Medicare physician payment.
Local Coverage Determination Clarification Act of 2017
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Physician and pharmacy reimbursement issues; Legislation to amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare; Site neutral payment reforms; Issues related to physician reimbursement for Part B drugs; Support for increased transparency and accountability in Medicare's local determination process (S.794/H.R. 3635); Issues as they relate to opioid abuse policy; General Medicare/Medicaid Issues; Issues related to reimbursement for radiation therapy services; 340B, education related to need for sensible reforms in 340B that protect indigent beneficiaries and community oncology practices; Pandemic and All Hazards Preparedness Act reauthorization.
Local Coverage Determination Clarification Act of 2017
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Physician and pharmacy reimbursement issues; Legislation to amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare; Site neutral payment reforms;Issues related to physician reimbursement for Part B drugs;Support for increased transparency and accountability in Medicare's local determination process (S.794/H.R. 3635); Issues as they relate to opioid abuse policy; General Medicare/Medicaid Issues; Issues related to reimbursement for radiation therapy services; 340B, education related to need for sensible reforms in 340B that protect indigent beneficiaries and community oncology practices; Pandemic and All Hazards Preparedness Act reauthorization; issues related to step therapy policies in Medicare Advantage plans; Medicare physician payment; Issues related to an alternative payment model for radiation oncology services; Issues related to the Center for Medicare and Medicaid Innovation; Issues related to the ANPRM International Pricing Index Model for Medicare Part B Drugs.
Local Coverage Determination Clarification Act of 2017
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Physician and pharmacy reimbursement issues; Legislation to amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare; Site neutral payment reforms; Issues related to physician reimbursement for Part B drugs; Support for increased transparency and accountability in Medicare's local determination process (S.794/H.R. 3635); Issues as they relate to opioid abuse policy; General Medicare/Medicaid Issues; Issues related to reimbursement for radiation therapy services; 340B, education related to need for sensible reforms in 340B that protect indigent beneficiaries and community oncology practices; Pandemic and All Hazards Preparedness Act reauthorization.
21st Century Cures Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Implementation of Comprehensive Addiction and Recovery Act (CARA) PL 114-198 and education regarding opioid treatment and prevention; Implementation of 21st Century Cures (H.R. 34), advocacy related to healthcare technology and innovation issues; E-Rx (H.R.3528), advocacy related to electronic prescriptions of medications; Implementation of FY'2018 NDAA provision related to e-Commerce portals;education about potential improvements to Prescription Drug Monitoring Programs.
21st Century Cures Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Implementation of Comprehensive Addiction and Recovery Act (CARA) PL 114-198 and education regarding opioid treatment and prevention; Implementation of 21st Century Cures (H.R. 34), advocacy related to healthcare technology and innovation issues; E-Rx (H.R.3528), advocacy related to electronic prescriptions of medications; Implementation of FY'2018 NDAA provision related to e-Commerce portals; education about potential improvements to Prescription Drug Monitoring Programs; H.R. 6 Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act.
21st Century Cures Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Implementation of Comprehensive Addiction and Recovery Act (CARA) PL 114-198 and education regarding opioid treatment and prevention; Implementation of 21st Century Cures (H.R. 34), advocacy related to healthcare technology and innovation issues; E-Rx (H.R.3528), advocacy related to electronic prescriptions of medications; Implementation of FY'2018 NDAA provision related to e-Commerce portals; education about potential improvements to Prescription Drug Monitoring Programs; H.R. 6 Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act.
21st Century Cures Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Implementation of Comprehensive Addiction and Recovery Act (CARA) PL 114-198 and education regarding opioid treatment and prevention; Implementation of 21st Century Cures (H.R. 34), advocacy related to healthcare technology and innovation issues; E-Rx (H.R.3528), advocacy related to electronic prescriptions of medications.
21st Century Cures Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Implementation of Comprehensive Addiction and Recovery Act (CARA) PL 114-198 and education regarding opioid treatment and prevention; Implementation of 21st Century Cures (H.R. 34), advocacy related to healthcare technology and innovation issues; E-Rx (H.R.3528), advocacy related to electronic prescriptions of medications; Implementation of FY'2018 NDAA provision related to e-Commerce portals; education about potential improvements to Prescription Drug Monitoring Programs; H.R. 6 Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act; Education about improvements to Prescription Drug Monitoring programs that would promote greater efficiency and utility at the pharmacy and other issues related to opioid abuse.
Improving Transparency and Accuracy in Medicare Part D Spending Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytics dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect renumeration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services.
Prescription Drug Price Transparency Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytics dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect renumeration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services.
Prescription Drug Price Transparency Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytics dispensed by community-based cancer clinics (H.R. 1316)
Every Prescription Conveyed Securely Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Implementation of Comprehensive Addiction and Recovery Act (CARA) PL 114-198 and education regarding opioid treatment and prevention; Implementation of 21st Century Cures (H.R. 34), advocacy related to healthcare technology and innovation issues; E-Rx (H.R.3528), advocacy related to electronic prescriptions of medications.
Local Coverage Determination Clarification Act of 2018
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Physician and pharmacy reimbursement issues; Legislation to amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare; Site neutral payment reforms; Issues related to physician reimbursement for Part B drugs; Support for increased transparency and accountability in Medicare's local determination process (S.794/H.R. 3635); Issues as they relate to opioid abuse policy; General Medicare/Medicaid Issues.
Local Coverage Determination Clarification Act of 2018
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Physician and pharmacy reimbursement issues; Legislation to amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare; Site neutral payment reforms; Issues related to physician reimbursement for Part B drugs; Support for increased transparency and accountability in Medicare's local determination process (S.794/H.R. 3635); Issues as they relate to opioid abuse policy; General Medicare/Medicaid Issues; Issues related to reimbursement for radiation therapy services; 340B, education related to need for sensible reforms in 340B that protect indigent beneficiaries and community oncology practices.
Pharmacy and Medically Underserved Areas Enhancement Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytics dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect renumeration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services.
An original bill to provide for reconciliation pursuant to title II of the concurrent resolution on the budget for fiscal year 2018.
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
H.R./S.1: Tax Cuts and Jobs Act.
Local Coverage Determination Clarification Act of 2017
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Physician and pharmacy reimbursement issues; Legislation to amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare; Site neutral payment reforms; Issues related to physician reimbursement for Part B drugs; Support for increased transparency and accountability in Medicare's local determination process (S.794/H.R. 3635); Issues as they relate to opioid abuse policy; General Medicare/Medicaid Issues; Issues related to reimbursement for radiation therapy services; 340B, education related to need for sensible reforms in 340B that protect indigent beneficiaries and community oncology practices.
Local Coverage Determination Clarification Act of 2017
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Physician and pharmacy reimbursement issues; Legislation to amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare; Site neutral payment reforms; Issues related to physician reimbursement for Part B drugs; Support for increased transparency and accountability in Medicare's local determination process (S.794/H.R. 3635); Issues as they relate to opioid abuse policy; General Medicare/Medicaid Issues.
21st Century Cures Act
Client: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS · Firm: MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP)
Implementation of Comprehensive Addiction and Recovery Act (CARA) PL 114-198 and education regarding opioid treatment and prevention; Implementation of 21st Century Cures (H.R. 34), advocacy related to healthcare technology and innovation issues; E-Rx (H.R.3528), advocacy related to electronic prescriptions of medications.
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytics dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect renumeration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services; H.R. 6688, The Analyzing and Leveraging Existing Rx Transactions (ALERT) Act.
Physician and pharmacy reimbursement issues;Legislation to amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare; Site neutral payment reforms;Issues related to physician reimbursement for Part B drugs;Support for increased transparency and accountability in Medicare's local determination process (S.794/H.R. 3635); Issues as they relate to opioid abuse policy; General Medicare/Medicaid Issues; Issues related to reimbursement for radiation therapy services; 340B, education related to need for sensible reforms in 340B that protect indigent beneficiaries and community oncology practices; Pandemic and All Hazards Preparedness Act reauthorization; issues related to step therapy policies in Medicare Advantage plans; Medicare physician payment; Issues related to an alternative payment model for radiation oncology services; Issues related to the Center for Medicare and Medicaid Innovation; Issues related to the ANPRM International Pricing Index Model for Medicare Part B Drugs; Chimeric Antigen Receptor (CAR) T-Cell Therapy coverage.
H.R./S.1: Tax Cuts and Jobs Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytics dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect renumeration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services; H.R. 6688, The Analyzing and Leveraging Existing Rx Transactions (ALERT) Act.
USTR Section 301 proposed tariffs.
Physician and pharmacy reimbursement issues;Legislation to amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare; Site neutral payment reforms;Issues related to physician reimbursement for Part B drugs;Support for increased transparency and accountability in Medicare's local determination process (S.794/H.R. 3635); Issues as they relate to opioid abuse policy; General Medicare/Medicaid Issues; Issues related to reimbursement for radiation therapy services; 340B, education related to need for sensible reforms in 340B that protect indigent beneficiaries and community oncology practices; Pandemic and All Hazards Preparedness Act reauthorization; issues related to step therapy policies in Medicare Advantage plans; Medicare physician payment; Issues related to an alternative payment model for radiation oncology services; Issues related to the Center for Medicare and Medicaid Innovation; Issues related to the ANPRM International Pricing Index Model for Medicare Part B Drugs; Chimeric Antigen Receptor (CAR) T-Cell Therapy coverage.
H.R./S.1: Tax Cuts and Jobs Act.
Implementation of Comprehensive Addiction and Recovery Act (CARA) PL 114-198 and education regarding opioid treatment and prevention; Implementation of 21st Century Cures (H.R. 34), advocacy related to healthcare technology and innovation issues; E-Rx (H.R.3528), advocacy related to electronic prescriptions of medications; Implementation of FY'2018 NDAA provision related to e-Commerce portals; education about potential improvements to Prescription Drug Monitoring Programs; H.R. 6 Substance Use- Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act; Education about improvements to Prescription Drug Monitoring programs that would promote greater efficiency and utility at the pharmacy and other issues related to opioid abuse.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Implementation of Comprehensive Addiction and Recovery Act (CARA) PL 114-198 and education regarding opioid treatment and prevention; Implementation of 21st Century Cures (H.R. 34), advocacy related to healthcare technology and innovation issues; E-Rx (H.R.3528), advocacy related to electronic prescriptions of medications; Implementation of FY'2018 NDAA provision related to e-Commerce portals; education about potential improvements to Prescription Drug Monitoring Programs; H.R. 6 Substance Use- Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act; Education about improvements to Prescription Drug Monitoring programs that would promote greater efficiency and utility at the pharmacy and other issues related to opioid abuse.
USTR Section 301 proposed tariffs.
H.R./S.1: Tax Cuts and Jobs Act.
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytics dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect renumeration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services; H.R. 6688, The Analyzing and Leveraging Existing Rx Transactions (ALERT) Act.
Physician and pharmacy reimbursement issues;Legislation to amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare; Site neutral payment reforms;Issues related to physician reimbursement for Part B drugs;Support for increased transparency and accountability in Medicare's local determination process (S.794/H.R. 3635); Issues as they relate to opioid abuse policy; General Medicare/Medicaid Issues; Issues related to reimbursement for radiation therapy services; 340B, education related to need for sensible reforms in 340B that protect indigent beneficiaries and community oncology practices; Pandemic and All Hazards Preparedness Act reauthorization; issues related to step therapy policies in Medicare Advantage plans; Medicare physician payment; Issues related to an alternative payment model for radiation oncology services; Issues related to the Center for Medicare and Medicaid Innovation; Issues related to the ANPRM International Pricing Index Model for Medicare Part B Drugs; Chimeric Antigen Receptor (CAR) T-Cell Therapy coverage.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytics dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect renumeration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services; H.R. 6688, The Analyzing and Leveraging Existing Rx Transactions (ALERT) Act.
H.R./S.1: Tax Cuts and Jobs Act.
Physician and pharmacy reimbursement issues; Legislation to amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare; Site neutral payment reforms;Issues related to physician reimbursement for Part B drugs;Support for increased transparency and accountability in Medicare's local determination process (S.794/H.R. 3635); Issues as they relate to opioid abuse policy; General Medicare/Medicaid Issues; Issues related to reimbursement for radiation therapy services; 340B, education related to need for sensible reforms in 340B that protect indigent beneficiaries and community oncology practices; Pandemic and All Hazards Preparedness Act reauthorization; issues related to step therapy policies in Medicare Advantage plans; Medicare physician payment; Issues related to an alternative payment model for radiation oncology services; Issues related to the Center for Medicare and Medicaid Innovation; Issues related to the ANPRM International Pricing Index Model for Medicare Part B Drugs.
Implementation of Comprehensive Addiction and Recovery Act (CARA) PL 114-198 and education regarding opioid treatment and prevention; Implementation of 21st Century Cures (H.R. 34), advocacy related to healthcare technology and innovation issues; E-Rx (H.R.3528), advocacy related to electronic prescriptions of medications; Implementation of FY'2018 NDAA provision related to e-Commerce portals; education about potential improvements to Prescription Drug Monitoring Programs; H.R. 6 Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act; Education about improvements to Prescription Drug Monitoring programs that would promote greater efficiency and utility at the pharmacy and other issues related to opioid abuse.
USTR Section 301 proposed tariffs.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Physician and pharmacy reimbursement issues; Legislation to amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare; Site neutral payment reforms; Issues related to physician reimbursement for Part B drugs; Support for increased transparency and accountability in Medicare's local determination process (S.794/H.R. 3635); Issues as they relate to opioid abuse policy; General Medicare/Medicaid Issues; Issues related to reimbursement for radiation therapy services; 340B, education related to need for sensible reforms in 340B that protect indigent beneficiaries and community oncology practices; Pandemic and All Hazards Preparedness Act reauthorization; issues related to step therapy policies in Medicare Advantage plans; Medicare physician payment.
H.R./S.1: Tax Cuts and Jobs Act.
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytics dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect renumeration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services; H.R. 6688, The Analyzing and Leveraging Existing Rx Transactions (ALERT) Act.
USTR Section 301 proposed tariffs.
Implementation of Comprehensive Addiction and Recovery Act (CARA) PL 114-198 and education regarding opioid treatment and prevention; Implementation of 21st Century Cures (H.R. 34), advocacy related to healthcare technology and innovation issues; E-Rx (H.R.3528), advocacy related to electronic prescriptions of medications; Implementation of FY'2018 NDAA provision related to e-Commerce portals; education about potential improvements to Prescription Drug Monitoring Programs; H.R. 6 Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Implementation of Comprehensive Addiction and Recovery Act (CARA) PL 114-198 and education regarding opioid treatment and prevention; Implementation of 21st Century Cures (H.R. 34), advocacy related to healthcare technology and innovation issues; E-Rx (H.R.3528), advocacy related to electronic prescriptions of medications; Implementation of FY'2018 NDAA provision related to e-Commerce portals; education about potential improvements to Prescription Drug Monitoring Programs; H.R. 6 Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act.
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytics dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect renumeration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services.
USTR Section 301 proposed tariffs.
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytics dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect renumeration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services.
Physician and pharmacy reimbursement issues; Legislation to amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare; Site neutral payment reforms; Issues related to physician reimbursement for Part B drugs; Support for increased transparency and accountability in Medicare's local determination process (S.794/H.R. 3635); Issues as they relate to opioid abuse policy; General Medicare/Medicaid Issues; Issues related to reimbursement for radiation therapy services; 340B, education related to need for sensible reforms in 340B that protect indigent beneficiaries and community oncology practices; Pandemic and All Hazards Preparedness Act reauthorization.
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytics dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect renumeration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services; Issues related to reimbursement from the Department of Veterans Affairs.
Implementation of Comprehensive Addiction and Recovery Act (CARA) PL 114-198 and education regarding opioid treatment and prevention; Implementation of 21st Century Cures (H.R. 34), advocacy related to healthcare technology and innovation issues; E-Rx (H.R.3528), advocacy related to electronic prescriptions of medications.
Physician and pharmacy reimbursement issues; Legislation to amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare; Site neutral payment reforms; Issues related to physician reimbursement for Part B drugs; Support for increased transparency and accountability in Medicare's local determination process (S.794/H.R. 3635); Issues as they relate to opioid abuse policy; General Medicare/Medicaid Issues; Issues related to reimbursement for radiation therapy services; 340B, education related to need for sensible reforms in 340B that protect indigent beneficiaries and community oncology practices.
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytics dispensed by community-based cancer clinics (H.R. 1316)
Proposal to repeal LIFO; Corporate Tax Reform
Physician and pharmacy reimbursement issues; Legislation to amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare; Site neutral payment reforms; Issues related to physician reimbursement for Part B drugs; Support for increased transparency and accountability in Medicare's local determination process (S.794/H.R. 3635); Issues as they relate to opioid abuse policy; General Medicare/Medicaid Issues.
H.R./S.1: Tax Cuts and Jobs Act.
USTR Section 301 proposed tariffs.
Physician and pharmacy reimbursement issues; Legislation to amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare; Site neutral payment reforms; Issues related to physician reimbursement for Part B drugs; Support for increased transparency and accountability in Medicare's local determination process (S.794/H.R. 3635); Issues as they relate to opioid abuse policy; General Medicare/Medicaid Issues; Issues related to reimbursement for radiation therapy services; 340B, education related to need for sensible reforms in 340B that protect indigent beneficiaries and community oncology practices; Pandemic and All Hazards Preparedness Act reauthorization.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Implementation of Comprehensive Addiction and Recovery Act (CARA) PL 114-198 and education regarding opioid treatment and prevention; Implementation of 21st Century Cures (H.R. 34), advocacy related to healthcare technology and innovation issues; E-Rx (H.R.3528), advocacy related to electronic prescriptions of medications; Implementation of FY'2018 NDAA provision related to e-Commerce portals;education about potential improvements to Prescription Drug Monitoring Programs.
Physician and pharmacy reimbursement issues; Legislation to amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare; Site neutral payment reforms; Issues related to physician reimbursement for Part B drugs; Support for increased transparency and accountability in Medicare's local determination process (S.794/H.R. 3635); Issues as they relate to opioid abuse policy; General Medicare/Medicaid Issues; Issues related to reimbursement for radiation therapy services; 340B, education related to need for sensible reforms in 340B that protect indigent beneficiaries and community oncology practices; Pandemic and All Hazards Preparedness Act reauthorization.
H.R./S.1: Tax Cuts and Jobs Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
H.R./S.1: Tax Cuts and Jobs Act.
Implementation of Comprehensive Addiction and Recovery Act (CARA) PL 114-198 and education regarding opioid treatment and prevention; Implementation of 21st Century Cures (H.R. 34), advocacy related to healthcare technology and innovation issues; E-Rx (H.R.3528), advocacy related to electronic prescriptions of medications.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
H.R./S.1: Tax Cuts and Jobs Act.
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytics dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect renumeration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Incentives for health information technology including the adoption of electronic health records; Implementation of Comprehensive Addiction and Recovery Act (CARA) PL 114-198 and education regarding opioid treatment and prevention
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE